The deepest CDMO market in the world. Compare FDA-registered US contract manufacturers across biologics, sterile fill-finish, oral solid dose, and API — by capability, certification, and manufacturing site.
The United States is the largest pharmaceutical manufacturing market on earth, with more FDA-registered drug-manufacturing facilities than any other country. For US-market products, a domestic CDMO collapses the regulatory distance to the FDA, removes import friction, and shortens the cold chain for temperature-sensitive biologics — advantages that compound on commercial-scale programs.
Manufacturing clusters are geographically distinct. The Boston–Cambridge corridor anchors biologics and cell & gene therapy. North Carolina's Research Triangle carries deep small-molecule and drug-product capacity. San Francisco and San Diego anchor West Coast biologics, while the I-95 mid-Atlantic and the Midwest hold large-scale sterile and oral-solid-dose plants.
The BIOSECURE Act has made US capacity a strategic question, not just a logistics one. Sponsors that previously relied on certain offshore CDMOs are actively reshoring biologics and cell-therapy work to domestic partners, tightening capacity and making early engagement with a US CDMO more important than at any point in the last decade.
No companies found in this category yet. Check back soon.
Browse all CDMOsHow this list is built: companies appear here when they have a manufacturing site in United States in our facilities dataset and pass the marketplace eligibility gate (pharmaceutical contract manufacturers only — CROs, equipment suppliers, and other non-manufacturers are excluded). Read the full methodology for the eligibility gates and how our ranked lists are computed.
Our AI Matchmaker analyzes your project requirements and matches you with qualified United States manufacturing partners. Free for buyers.